Don’t wait, call now! You may be entitled to the financial compensation you deserve.

WHAT IS ELMIRON®:
Elmiron® is a commonly prescribed weak blood thinner (anti-coagulant) that is used to treat bladder pain or discomfort caused by cystitis of the bladder. It contains the active ingredient pentosan polysulfate sodium (PPS). Approved by the U.S. Food and Drug Administration (FDA) in 1996, pentosan polysulfate sodium (Elmiron®) is the only FDA approved oral medication designed to treat bladder pain and discomfort associated with interstitial cystitis (IC), a condition that affects millions of Americans each year. IC is more prevalent in women, and many use Elmiron® long-term to treat the disease. Elmiron® sales amount to at least $150 Million per year.
**In November 2018, the American Academy of Ophthalmology released a study that found a connection between long-term use of Elmiron® and vision problems. Another Elmiron® study released in May 2019 concluded that Elmiron® resulted in “potentially avoidable retinal degeneration phenomenon associated with chronic [Elmiron®] exposure.” Then the American Academy of Ophthalmology published another study in October 2019, which found that Elmiron® (pentosan polysuflate sodium) “appears to be toxic to the retina” and that about one-quarter of Elmiron® users may suffer from a form of macular degeneration or “Maculopathy.” Maculopathy is any disease that impacts the macula, which is the central part of the retina that is responsible for all central vision, most color vision, and fine detail. The type of maculopathy linked to Elmiron® is called pigmentary maculopathy, which according to studies, seems to be unique to Elmiron® users. If caught in its early stages, the damage may stop after taking medication but in late stages, the disease can lead to permanent vision loss. So far researchers have reported on one patient whose eye damage continued for years even after stopping Elmiron®.
Sources
**Elmiron® Findings from Ophthalmologists